CHMP Recommended Approval for Pebrilzo Biosimilar
The committee issued a positive opinion for the marketing authorization of a new breast cancer treatment.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you support the increased availability of biosimilar medications to reduce cancer treatment costs?
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of Pebrilzo. This biosimilar, developed by Biocon Biologics Ireland, is designed to treat HER2-positive breast cancer.
Why it matters
The recommendation marks a key regulatory step toward increasing the availability of lower-cost biosimilar treatment options for patients with HER2-positive breast cancer. Following this opinion, the European Commission will conduct a final review to determine if the product will receive formal marketing authorization.
Pebrilzo is formulated as a 420 mg concentrate solution for infusion. The CHMP based its positive opinion on a marketing authorization application review for the biosimilar's use across multiple stages of HER2-positive breast cancer.
The players
Biocon Biologics Ireland
This is a biopharmaceutical company that submitted the marketing authorization application for the biosimilar product.
Committee for Medicinal Products for Human Use
This is the branch of the European Medicines Agency responsible for evaluating marketing authorization applications for medicinal products.
European Commission
This is the executive branch of the European Union that makes final decisions regarding the approval of medical products.
The details
Biocon Biologics Ireland submitted the application for Pebrilzo, which functions as a biosimilar to existing Pertuzumab therapies. The European Public Assessment Report is expected to be published on the European Medicines Agency website following the final commission review.
Timeline
Biocon announced the receipt of the positive CHMP opinion on September 21, 2026.
The Big Picture
This development follows the rigorous regulatory pathways established by the European Medicines Agency's biosimilar regulatory framework. The recommendation highlights the ongoing integration of biosimilar therapies into the standard treatment paradigms for oncology.
The potential approval of this biosimilar may provide patients and healthcare providers with an additional, cost-effective treatment alternative for HER2-positive breast cancer. It does not alter current clinical routines until the European Commission issues its final authorization.
The takeaway
The move toward biosimilar adoption remains a core strategy in expanding access to expensive biological treatments for chronic illnesses. Patients should discuss available treatment options with their oncologists as new medications enter the market.
What happens next
The European Commission will proceed with a final review of the marketing authorization application to reach a formal decision.
Further reading
For more on the latest research and developments in oncology, visit the Cancer section.
Live Poll
Do you support the increased availability of biosimilar medications to reduce cancer treatment costs?
